Clinical efficacy of a new ciclopiroxolamine/zinc pyrithione shampoo in scalp seborrheic dermatitis treatment

European Journal of Dermatology

Volumn 16, Issue 5, 2006, Pages 558-564

  Lorette, Gérard ^a   Ermosilla, Valérie ^b   Decuyper, Michèle ^c   Farcet, Yolaine ^c   Flechet, Marie Laure ^c   Haziza, Jean Luc ^c   Ruer Mulard, Mireille ^c   Poirier, Jean Paul ^c   Durand, Jean Marc ^c   Garnier Calas, Marie Hélène ^c   Pouget, Marie Christine ^c   Weiller, Michel ^c   Nouira, Rafia ^c   Doss, Nejib ^c   Osman, Amel Ben ^c   Kamoun, Ridha ^c   Mokthar, Insaf ^c  

^a SERVICE DE DERMATOLOGIE   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^c NONE

Author keywords

Ciclopirox; Ketoconazole; Malassezia; Seborrheic dermatitis; Zinc pyrithione

Indexed keywords

ANTIFUNGAL AGENT; CICLOPIROXOLAMINE; KETOCONAZOLE; PYRITHIONE ZINC; SHAMPOO;

ADULT; ARTICLE; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; ERYTHEMA; FACE ERYTHEMA; FEMALE; GEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEBORRHEIC DERMATITIS; SINGLE BLIND PROCEDURE;

ADULT; AGED; ANTIFUNGAL AGENTS; DERMATITIS, SEBORRHEIC; DRUG COMBINATIONS; FEMALE; HAIR PREPARATIONS; HUMANS; KERATOLYTIC AGENTS; KETOCONAZOLE; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PYRIDINES; PYRIDONES; SCALP DERMATOSES;

EID: 33845249294     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2006.0031     Document Type: Article

References (33)

1. Johnson M-L, Roberts J. Prevalence of dermatological diseases among persons 1-74 years of age: United States. Advance data report No. 4. U.S. Department of Health, Education, and Welfare, 1977.
2. Gupta AK, Madzia SE, Batra R. Etiology and management of Seborrheic dermatitis. Dermatology 2004; 208: 89-93.
3. Gupta AK, Batra R, Bluhm R, et al. Skin diseases associated with Malassezia species. J Am Acad Dermatol 2004; 51: 785-98.
4. Nakabayashi A, Sei Y, Guillot J. Identification of Malassezia species isolated from patients with seborrhoeic dermatitis, atopic dermatitis, pityriasis versicolor and normal subjects. Med Mycol 2000; 38: 337-41.
5. Heng MC, Henderson CL, Barker DC, Haberfelde G. Correlation of Pityrosporum ovale density with clinical severity of seborrheic dermatitis as assessed by a simplified technique. J Am Acad Dermatol 1990; 23: 82-6.
6. Groisser D, Bottone EJ, Lebwohl M. Association of Pityrosporum orbiculare (Malassezia furfur) with seborrhoeic dermatitis in patients with acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol 1989; 20: 770-3.
7. Sandström Falk M-H, Tengvall Linder M, Johansson C, et al. The prevalence of Malassezia Yeasts in patients with atopic dermatitis, seborrhoeic dermatitis and healthy controls. Acta Derm Venereol 2005; 85: 17-23.
8. Gupta AK, Kohli Y, Summerbell RC, Faergemann J. Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. Med Mycol 2001; 39: 243-51.
9. Gemmer CM, DeAngelis YM, Theelen B, et al. Fast, noninvasive method for molecular detection and differentiation of Malassezia yeast species on human skin and application of the method to dandruff microbiology. J Clin Microbiol 2002; 40: 3350-7.
10. Ford GP, Farr PM, Ive FA, Shuster S. The response of seborrhoeic dermatitis to ketoconazole. Br J Dermatol 1984; 111: 603-7.
11. Ortonne JP, Lacour JP, Vitetta A, Le Fichoux Y. Comparative study of ketoconazole 2% foaming gel and betamethasone dipropionate 0.05% lotion in the treatment of seborrhoeic dermatitis in adults. Dermatology 1992; 184: 275-80.
12. Shuttleworth D, Squire RA, Boorman GC, Goode K. Comparative clinical efficacy of shampoos containing cliclopirox olamine (1.5%) or ketoconazole (2%; Nizoral®) for the control of dandruff/seborrhoeic dermatitis. J Dermatolog Treat 1998; 9: 157-62.
13. Squire RA, Goode K. A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. J Dermatolog Treat 2002; 13: 51-60.
14. Lebwohl M, Plott T. Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrhoeic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial. Int J Dermatol 2004; 43(Suppl 1): 17-20.
15. Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol 2004; 18: 13-26.
16. Faergemann J. Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol 2000; 1: 75-80.
17. Faergemann J. Seborrhoeic dermatitis and Pityrosporum orbiculare: treatment of seborrhoeic dermatitis of the scalp with miconazole-hydrocortisone (Daktacort), miconazole and hydrocortisone. Br J Dermatol 1986; 114: 695-700.
18. Saple DG, Ravichandran G, Desai A. Evaluation of safety and efficacy of ketoconazole 2% and zinc pyrithione 1% shampoo in patients with moderate to severe dandruff-a postmarketing study. J Indian Med Assoc 2000; 98: 810-1.
19. Lassus A, Nolting KS, Savopoulos C. Comparison of ciclopirox olamine 1% cream with ciclopirox 1%-hydrocortisone acetate 1% cream in the treatment of inflamed superficial mycoses. Clin Ther 1988; 10: 594-9.
20. Rosen T, Schell BJ, Orengo I. Anti-inflammatory activity of anti-fungal preparations. Int J Dermatol 1997; 36: 788-92.
21. Shuster S, Meynadier J, Kerl H, Nolting S. Treatment and prophylaxis of seborrheic dermatitis of the scalp with antipityrosporal 1% ciclopirox shampoo. Arch Dermatol 2005; 141: 47-52.
22. Altmeyer P, Hoffmann K, Loprox Shampoo Dosing Concentration Study Group. Efficacy of different concentrations of ciclopirox shampoo for the treatment of seborrheic dermatitis of the scalp: results of a randomized, double-blind, vehicle-controlled trial. Int J Dermatol 2004; 43(Suppl 1): 9-12.
23. Lee JH, Lee HS, Eun HC, Cho KH. Successful treatment of dandruff with 1.5% ciclopirox olamine shampoo in Korea. J Dermatolog Treat 2003; 14: 212-5.
24. Van Cutsem J, Van Gerven F, Fransen J, Schrooten P, Janssen PA. The in vitro antifungal activity of ketoconazole, zinc pyrithione, and selenium sulfide against Pityrosporum and their efficacy as a shampoo in the treatment of experimental pityrosporosis in guinea pigs. J Am Acad Dermatol 1990; 22: 993-8.
25. McGinley KJ, Leyden JJ. Antifungal activity of dermatological shampoos. Arch Dermatol Res 1982; 272: 339-42.
26. Marks R, Pearse AD, Walker AP. The effects of a shampoo containing zinc pyrithione on the control of dandruff. Br J Dermatol 1985; 112: 415-22.
27. Warner RR, Schwartz JR, Boissy Y, Dawson Jr. TL. Dandruff has an altered stratum corneum ultrastructure that is improved with zinc pyrithione shampoo. J Am Acad Dermatol 2001; 45: 897-903.
28. Ware J, Kosinski M, Keller S. A 12-item short-form health survey. Construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220-33.
29. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-6.
30. Danby FW, Maddin WS, Margesson LJ, Rosenthal D. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol 1993; 29: 1008-12.
31. Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br J Dermatol 1995; 132: 441-5.
32. Chosidow O, Maurette C, Dupuy P. Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrheic dermatitis. Dermatology 2003; 206: 233-40.
33. Pierard-Franchimont C, Pierard GE, Arrese JE, De Doncker P. Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrhoeic dermatitis: clinical, squamometric and mycological assessments. Dermatology 2001; 202: 171-6.